Venetoclax

BNF:
Not listed
Status:
Red
Decision Date:
February 2017
 

Comments

RED1,2,3: NICE TA487 - for treating chronic lymphocytic leukaemia. (Decision date - December 2017)

RED1,2,3: NICE TA561 -  with rituximab for previously treated chronic lymphocyctic leukaemia. (Decision date  - March 2019)

RED1,2,3: NICE TA663 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. (Decision date - January 2021) 

NHSE commissioned drug.

 

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire CCG

Derby and Derbyshire CCG